PALO ALTO, Calif.--(BUSINESS WIRE)-- Anacor Pharmaceuticals announced today that David Perry, the company’s Chief Executive Officer, will provide a company overview at the following investor conferences in March:
- 2011 Citi Global Health Care Conference at 2:30 p.m. ET on Wednesday, March 2, 2011 in New York, New York.
- Cowen and Company 31st Annual Health Care Conference at 8:00 a.m. ET on Tuesday, March 8, 2011 in Boston, Massachusetts.
Both events will be webcast live and may be accessed under “Events and Presentations” on the Investors page of Anacor’s website at www.anacor.com. A replay will also be available for three months following each presentation.
About Anacor Pharmaceuticals
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered five clinical compounds which are currently in development, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK ‘052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis. For more information visit http://www.anacor.com.
CONTACT:
Anacor Pharmaceuticals
DeDe Sheel, 650-543-7575
Director, Investor Relations and Corporate Communications
KEYWORDS: United States North America California Massachusetts New York
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Pharmaceutical Other Health Research Other Science Science
MEDIA: